Pharma Journalist -

Galderma announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now…
Read More...

MaxCyte, Inc. announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the…
Read More...

Merck, known as MSD outside of the United States and Canada, announced that Health Canda has granted approval for KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, as a treatment for…
Read More...

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently…
Read More...

AbbVie and Xilio Therapeutics, Inc. a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, announced…
Read More...

Boehringer Ingelheim announced that the FIBRONEER-ILD trial met its primary endpoint, which was the absolute change from baseline in forced vital capacity (FVC) at week 52 versus…
Read More...

Novartis announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab,…
Read More...

Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced the company has reached an exclusive…
Read More...

Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced…
Read More...

Immuneering Corporation, a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, announced a clinical…
Read More...